Evaluating the effect of supplementation with Bacillus clausii on therapeutic outcomes in atopic eczema—Results of an observer-blinded parallel-group randomized controlled study
Background: Atopic dermatitis (AD) is an itchy, chronic or chronically relapsing, inflammatory skin condition. Aims: To study the effectiveness of probiotic supplementation (Bacillus clausii) in achieving clinical remission, preventing relapse and its effect on immunological profile in children with...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Indian Journal of Dermatology |
| Subjects: | |
| Online Access: | http://www.e-ijd.org/article.asp?issn=0019-5154;year=2022;volume=67;issue=2;spage=121;epage=126;aulast=Sharma |
| _version_ | 1811343829714862080 |
|---|---|
| author | Richa Sharma Sanjeev Handa Rahul Mahajan Dipankar De Naresh Sachdeva |
| author_facet | Richa Sharma Sanjeev Handa Rahul Mahajan Dipankar De Naresh Sachdeva |
| author_sort | Richa Sharma |
| collection | DOAJ |
| description | Background: Atopic dermatitis (AD) is an itchy, chronic or chronically relapsing, inflammatory skin condition. Aims: To study the effectiveness of probiotic supplementation (Bacillus clausii) in achieving clinical remission, preventing relapse and its effect on immunological profile in children with AD. Methods: In this randomized controlled study, 114 children with AD were randomized into two groups (57 each): Group A received conventional treatment, along with Bacillus clausii (Strains O/C, N/R, SIN and T) suspension available as Enterogermina® at the dose 2 billion spores/5 ml twice daily for 8 weeks and Group B receiving conventional treatment only. Baseline and follow-up SCORAD were assessed at 0, 4, 8, 12, 16, 20 and 24 weeks. Serum IL-17A levels were measured at baseline and 12 weeks. Results: There was no significant difference in mean SCORAD between the two groups at baseline, 12 weeks (p = 0.21) and 24 weeks (p = 0.26). The two groups did not differ significantly in terms of the number of patients who achieved SCORAD 90 (p = 0.19), SCORAD 75 (p = 0.59), and those who relapsed (p = 0.5). IL-17A levels were not significantly different between the two groups at baseline and 12 weeks (p = 0.7). There was no statistically significant correlation between IL-17A levels and AD severity. Limitations: Lack of double-blinding, lack of the use of placebo and a short follow-up period were the limitations of the present study. Conclusion: Administration of the probiotic Bacillus clausii in addition to conventional treatment does not offer any additional benefit in inducing remission or prevention relapse in AD. |
| first_indexed | 2024-04-13T19:37:04Z |
| format | Article |
| id | doaj.art-b8cb8583c8134a78a33766593e1e029d |
| institution | Directory Open Access Journal |
| issn | 0019-5154 1998-3611 |
| language | English |
| last_indexed | 2024-04-13T19:37:04Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Dermatology |
| spelling | doaj.art-b8cb8583c8134a78a33766593e1e029d2022-12-22T02:33:01ZengWolters Kluwer Medknow PublicationsIndian Journal of Dermatology0019-51541998-36112022-01-0167212112610.4103/ijd.ijd_587_21Evaluating the effect of supplementation with Bacillus clausii on therapeutic outcomes in atopic eczema—Results of an observer-blinded parallel-group randomized controlled studyRicha SharmaSanjeev HandaRahul MahajanDipankar DeNaresh SachdevaBackground: Atopic dermatitis (AD) is an itchy, chronic or chronically relapsing, inflammatory skin condition. Aims: To study the effectiveness of probiotic supplementation (Bacillus clausii) in achieving clinical remission, preventing relapse and its effect on immunological profile in children with AD. Methods: In this randomized controlled study, 114 children with AD were randomized into two groups (57 each): Group A received conventional treatment, along with Bacillus clausii (Strains O/C, N/R, SIN and T) suspension available as Enterogermina® at the dose 2 billion spores/5 ml twice daily for 8 weeks and Group B receiving conventional treatment only. Baseline and follow-up SCORAD were assessed at 0, 4, 8, 12, 16, 20 and 24 weeks. Serum IL-17A levels were measured at baseline and 12 weeks. Results: There was no significant difference in mean SCORAD between the two groups at baseline, 12 weeks (p = 0.21) and 24 weeks (p = 0.26). The two groups did not differ significantly in terms of the number of patients who achieved SCORAD 90 (p = 0.19), SCORAD 75 (p = 0.59), and those who relapsed (p = 0.5). IL-17A levels were not significantly different between the two groups at baseline and 12 weeks (p = 0.7). There was no statistically significant correlation between IL-17A levels and AD severity. Limitations: Lack of double-blinding, lack of the use of placebo and a short follow-up period were the limitations of the present study. Conclusion: Administration of the probiotic Bacillus clausii in addition to conventional treatment does not offer any additional benefit in inducing remission or prevention relapse in AD.http://www.e-ijd.org/article.asp?issn=0019-5154;year=2022;volume=67;issue=2;spage=121;epage=126;aulast=Sharmaatopic eczemabacillus clausiiprobiotics |
| spellingShingle | Richa Sharma Sanjeev Handa Rahul Mahajan Dipankar De Naresh Sachdeva Evaluating the effect of supplementation with Bacillus clausii on therapeutic outcomes in atopic eczema—Results of an observer-blinded parallel-group randomized controlled study Indian Journal of Dermatology atopic eczema bacillus clausii probiotics |
| title | Evaluating the effect of supplementation with Bacillus clausii on therapeutic outcomes in atopic eczema—Results of an observer-blinded parallel-group randomized controlled study |
| title_full | Evaluating the effect of supplementation with Bacillus clausii on therapeutic outcomes in atopic eczema—Results of an observer-blinded parallel-group randomized controlled study |
| title_fullStr | Evaluating the effect of supplementation with Bacillus clausii on therapeutic outcomes in atopic eczema—Results of an observer-blinded parallel-group randomized controlled study |
| title_full_unstemmed | Evaluating the effect of supplementation with Bacillus clausii on therapeutic outcomes in atopic eczema—Results of an observer-blinded parallel-group randomized controlled study |
| title_short | Evaluating the effect of supplementation with Bacillus clausii on therapeutic outcomes in atopic eczema—Results of an observer-blinded parallel-group randomized controlled study |
| title_sort | evaluating the effect of supplementation with bacillus clausii on therapeutic outcomes in atopic eczema results of an observer blinded parallel group randomized controlled study |
| topic | atopic eczema bacillus clausii probiotics |
| url | http://www.e-ijd.org/article.asp?issn=0019-5154;year=2022;volume=67;issue=2;spage=121;epage=126;aulast=Sharma |
| work_keys_str_mv | AT richasharma evaluatingtheeffectofsupplementationwithbacillusclausiiontherapeuticoutcomesinatopiceczemaresultsofanobserverblindedparallelgrouprandomizedcontrolledstudy AT sanjeevhanda evaluatingtheeffectofsupplementationwithbacillusclausiiontherapeuticoutcomesinatopiceczemaresultsofanobserverblindedparallelgrouprandomizedcontrolledstudy AT rahulmahajan evaluatingtheeffectofsupplementationwithbacillusclausiiontherapeuticoutcomesinatopiceczemaresultsofanobserverblindedparallelgrouprandomizedcontrolledstudy AT dipankarde evaluatingtheeffectofsupplementationwithbacillusclausiiontherapeuticoutcomesinatopiceczemaresultsofanobserverblindedparallelgrouprandomizedcontrolledstudy AT nareshsachdeva evaluatingtheeffectofsupplementationwithbacillusclausiiontherapeuticoutcomesinatopiceczemaresultsofanobserverblindedparallelgrouprandomizedcontrolledstudy |